Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
M&A / Property

TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box

By The Northwire Desk — AI Analysis Mar 24, 2026 · 07:01 VIVI · 0.76 TempraMed Technologies Ltd.
VIVI · Price

Executive Summary

  • TempraMed Technologies Ltd. received formal grant of a Chinese patent (CNIPA No. 202310499587.4) covering core innovations of its upcoming VIVI Box™ multi‑medication storage platform.
  • The patent, filed in 2019, is effective through October 23 2039 and includes 44 claims protecting thermal‑insulation and smart‑monitoring architecture.
  • The grant strengthens TempraMed’s IP position in China, supports its strategy to launch VIVI Box™ by the end of 2026, and underpins planned engagements with premium appliance manufacturers across Asia.

Key Details

  • Patent Grant: Chinese patent officially granted on March 17 2026; application filed October 24 2019 (CNIPA No. 202310499587.4).
  • Scope & Term: 44 claims covering thermal‑insulation, continuous temperature protection during power interruptions, portable travel functionality, and cloud‑based smart content tracking; term extends to October 23 2039.
  • Product Impact: Protects core technology of the VIVI Box™ – a multi‑medication storage box slated for market launch at the end of 2026, adding to TempraMed’s existing four‑product portfolio.
  • Commercial Opportunities: Enables strategic engagement with appliance manufacturers in Asia’s premium refrigeration sector and supports broader commercialization roadmap into multi‑dose, multi‑format medication storage systems.
  • Strategic Context: Follows recent milestones including a similar patent grant in South Korea, new distribution agreements, and validation of ROI models for insurance payors.
  • CEO Statement: Ron Nagar highlighted the grant as a “significant milestone” that strengthens TempraMed’s global IP strategy and expands its presence in China, a key market for advanced healthcare solutions.

Notable Quotes

“The formal grant of our Chinese patent represents a significant milestone in TempraMed's global intellectual property strategy,” – Ron Nagar, CEO
“Protecting our core innovations remains fundamental to unlocking long‑term shareholder value and establishing global leadership in temperature‑controlled medication management.” – Ron Nagar, CEO

Read the original news release →

More from TempraMed Technologies Ltd.

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property